Letters to the Editor

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston Salem, NC
The University of Texas MD Anderson Cancer Center, Houston, TX
Leipzig University Hospital, Leipzig
Princess Margaret Cancer Centre, Toronto, Ontario
Hadassah-Hebrew University Medical Center, Jerusalem
Miguel Servet University Hospital and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Zaragoza
Institut Universitaire du Cancer de Toulouse, Université de Toulouse III, Toulouse
Université Paris Cité, AP-HP, Ho_pital Saint-Louis, Centre d’Investigations Cliniques, INSERM, CIC1427, Paris
Washington University School of Medicine, St. Louis, MO
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Department of Hematology, University Hospitals Leuven and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium
University of Insubria, Varese
University of Florence and AOU Careggi, Florence
Somogy County Mór Kaposi General Hospital, Kaposvár, Hungary
Institute of Hematology and Transfusion Medicine, Warsaw, Poland
Department of Hematological Oncology, Oncology Specialist Hospital, Brzozow, Poland
Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
University of Miyazaki, Miyazaki, Japan
Guy's and St Thomas' NHS Foundation Trust, London
Sierra Oncology, Inc., San Mateo, CA
Sierra Oncology, Inc., San Mateo, CA
Sierra Oncology, Inc., San Mateo, CA
Sierra Oncology, Inc., San Mateo, CA
Guy's and St Thomas' NHS Foundation Trust, London
Vol. 109 No. 2 (2024): February, 2024 https://doi.org/10.3324/haematol.2023.283106